These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39332508)

  • 1. Retinal damage promotes mitochondrial transfer in the visual system of a mouse model of Leber hereditary optic neuropathy.
    Ezan P; Hardy E; Bemelmans A; Taiel M; Dossi E; Rouach N
    Neurobiol Dis; 2024 Oct; 201():106681. PubMed ID: 39332508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report.
    Newman NJ; Schniederjan M; Mendoza PR; Calkins DJ; Yu-Wai-Man P; Biousse V; Carelli V; Taiel M; Rugiero F; Singh P; Rogue A; Sahel JA; Ancian P
    BMC Neurol; 2022 Jul; 22(1):257. PubMed ID: 35820885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.
    Newman NJ; Yu-Wai-Man P; Subramanian PS; Moster ML; Wang AG; Donahue SP; Leroy BP; Carelli V; Biousse V; Vignal-Clermont C; Sergott RC; Sadun AA; Rebolleda Fernández G; Chwalisz BK; Banik R; Bazin F; Roux M; Cox ED; Taiel M; Sahel JA;
    Brain; 2023 Apr; 146(4):1328-1341. PubMed ID: 36350566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial.
    Koilkonda RD; Yu H; Chou TH; Feuer WJ; Ruggeri M; Porciatti V; Tse D; Hauswirth WW; Chiodo V; Boye SL; Lewin AS; Neuringer M; Renner L; Guy J
    JAMA Ophthalmol; 2014 Apr; 132(4):409-20. PubMed ID: 24457989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant NADH dehydrogenase subunit 4 gene delivery to mitochondria by targeting sequence-modified adeno-associated virus induces visual loss and optic atrophy in mice.
    Yu H; Ozdemir SS; Koilkonda RD; Chou TH; Porciatti V; Chiodo V; Boye SL; Hauswirth WW; Lewin AS; Guy J
    Mol Vis; 2012; 18():1668-83. PubMed ID: 22773905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular stress enhances contralateral transfer of lenadogene nolparvovec gene therapy through astrocyte networks.
    McGrady NR; Boal AM; Risner ML; Taiel M; Sahel JA; Calkins DJ
    Mol Ther; 2023 Jul; 31(7):2005-2013. PubMed ID: 37016579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution of intravitreal
    Calkins DJ; Yu-Wai-Man P; Newman NJ; Taiel M; Singh P; Chalmey C; Rogue A; Carelli V; Ancian P; Sahel JA
    Mol Ther Methods Clin Dev; 2021 Dec; 23():307-318. PubMed ID: 34729378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study.
    Biousse V; Newman NJ; Yu-Wai-Man P; Carelli V; Moster ML; Vignal-Clermont C; Klopstock T; Sadun AA; Sergott RC; Hage R; Esposti S; La Morgia C; Priglinger C; Karanja R; Blouin L; Taiel M; Sahel JA;
    J Neuroophthalmol; 2021 Sep; 41(3):309-315. PubMed ID: 34415265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: biodistribution and toxicology profile.
    Koilkonda R; Yu H; Talla V; Porciatti V; Feuer WJ; Hauswirth WW; Chiodo V; Erger KE; Boye SL; Lewin AS; Conlon TJ; Renner L; Neuringer M; Detrisac C; Guy J
    Invest Ophthalmol Vis Sci; 2014 Oct; 55(12):7739-53. PubMed ID: 25342621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.
    Yang S; Ma SQ; Wan X; He H; Pei H; Zhao MJ; Chen C; Wang DW; Dong XY; Yuan JJ; Li B
    EBioMedicine; 2016 Aug; 10():258-68. PubMed ID: 27426279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.
    Yu-Wai-Man P; Newman NJ; Carelli V; Moster ML; Biousse V; Sadun AA; Klopstock T; Vignal-Clermont C; Sergott RC; Rudolph G; La Morgia C; Karanjia R; Taiel M; Blouin L; Burguière P; Smits G; Chevalier C; Masonson H; Salermo Y; Katz B; Picaud S; Calkins DJ; Sahel JA
    Sci Transl Med; 2020 Dec; 12(573):. PubMed ID: 33298565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell therapy using retinal progenitor cells shows therapeutic effect in a chemically-induced rotenone mouse model of Leber hereditary optic neuropathy.
    Mansergh FC; Chadderton N; Kenna PF; Gobbo OL; Farrar GJ
    Eur J Hum Genet; 2014 Nov; 22(11):1314-20. PubMed ID: 24569607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results.
    Guy J; Feuer WJ; Davis JL; Porciatti V; Gonzalez PJ; Koilkonda RD; Yuan H; Hauswirth WW; Lam BL
    Ophthalmology; 2017 Nov; 124(11):1621-1634. PubMed ID: 28647203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results.
    Feuer WJ; Schiffman JC; Davis JL; Porciatti V; Gonzalez P; Koilkonda RD; Yuan H; Lalwani A; Lam BL; Guy J
    Ophthalmology; 2016 Mar; 123(3):558-70. PubMed ID: 26606867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model.
    Yu H; Koilkonda RD; Chou TH; Porciatti V; Ozdemir SS; Chiodo V; Boye SL; Boye SE; Hauswirth WW; Lewin AS; Guy J
    Proc Natl Acad Sci U S A; 2012 May; 109(20):E1238-47. PubMed ID: 22523243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect Comparison of Lenadogene Nolparvovec Gene Therapy Versus Natural History in Patients with Leber Hereditary Optic Neuropathy Carrying the m.11778G>A MT-ND4 Mutation.
    Carelli V; Newman NJ; Yu-Wai-Man P; Biousse V; Moster ML; Subramanian PS; Vignal-Clermont C; Wang AG; Donahue SP; Leroy BP; Sergott RC; Klopstock T; Sadun AA; Rebolleda Fernández G; Chwalisz BK; Banik R; Girmens JF; La Morgia C; DeBusk AA; Jurkute N; Priglinger C; Karanjia R; Josse C; Salzmann J; Montestruc F; Roux M; Taiel M; Sahel JA;
    Ophthalmol Ther; 2023 Feb; 12(1):401-429. PubMed ID: 36449262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of All Patient Groups.
    Lam BL; Feuer WJ; Davis JL; Porciatti V; Yu H; Levy RB; Vanner E; Guy J
    Am J Ophthalmol; 2022 Sep; 241():262-271. PubMed ID: 35271811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset.
    Newman NJ; Yu-Wai-Man P; Carelli V; Moster ML; Biousse V; Vignal-Clermont C; Sergott RC; Klopstock T; Sadun AA; Barboni P; DeBusk AA; Girmens JF; Rudolph G; Karanjia R; Taiel M; Blouin L; Smits G; Katz B; Sahel JA;
    Ophthalmology; 2021 May; 128(5):649-660. PubMed ID: 33451738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical research progress of gene therapy for Leber hereditary optic neuropathy].
    Wu YJ; Li WS
    Zhonghua Yan Ke Za Zhi; 2018 Aug; 54(8):636-640. PubMed ID: 30107658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial.
    Lam BL; Feuer WJ; Schiffman JC; Porciatti V; Vandenbroucke R; Rosa PR; Gregori G; Guy J
    JAMA Ophthalmol; 2014 Apr; 132(4):428-36. PubMed ID: 24525545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.